Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 13/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800132 | 1.00 | HSD17B3 (0.46) | HSD17B3GAAALOX5APFEN1NOTUM | |
| SCHEMBL4801450 | 0.89 | HSD17B3 (0.56) | HSD17B3GAANOTUM | |
| SCHEMBL4801463 | 0.89 | HSD17B3 (0.56) | HSD17B3GAANOTUM | |
| SCHEMBL4796170 | 0.89 | HSD17B3 (0.54) | HSD17B3GAAALOX5APFEN1NOTUM | |
| SCHEMBL4796176 | 0.89 | HSD17B3 (0.54) | HSD17B3GAAALOX5APFEN1NOTUM | |
| SCHEMBL4799504 | 0.89 | HSD17B3 (0.46) | HSD17B3ALOX5APFEN1NOTUMP2RX4 | |
| SCHEMBL4799514 | 0.89 | HSD17B3 (0.46) | HSD17B3ALOX5APFEN1NOTUMP2RX4 | |
| SCHEMBL4801178 | 0.86 | HSD17B3 (0.41) | HSD17B3GAAALOX5APFEN1KDM4E | |
| SCHEMBL4801187 | 0.86 | HSD17B3 (0.41) | HSD17B3GAAALOX5APFEN1KDM4E | |
| SCHEMBL4796190 | 0.81 | HSD17B3 (0.48) | HSD17B3NOTUMP2RX4CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885GAA 811/4885ALOX5AP 3649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.